伏立康唑与米替福新针对临床相关霉菌的体外联合应用
In vitro combination of voriconazole and miltefosine against clinically relevant molds.
作者信息
Imbert S, Palous M, Meyer I, Dannaoui E, Mazier D, Datry A, Fekkar A
机构信息
AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France.
Université Paris-Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France.
出版信息
Antimicrob Agents Chemother. 2014 Nov;58(11):6996-8. doi: 10.1128/AAC.03212-14. Epub 2014 Sep 8.
Abstract
Invasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus. Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.
摘要
丝状真菌引起的侵袭性感染对免疫功能低下的患者构成重大威胁。对抗真菌药物的固有/获得性耐药可能需要联合治疗。我们评估了伏立康唑与米替福新的潜在联合作用，米替福新是一种对33种临床相关霉菌分离株具有抗真菌活性的原研药物，包括对唑类敏感和耐药的曲霉菌。以完全抑制作为终点，32/33株分离株的相互作用为无关。另一个50%抑制终点显示14/33株分离株有协同相互作用。未出现拮抗作用。
相似文献
1
In vitro combination of voriconazole and miltefosine against clinically relevant molds.伏立康唑与米替福新针对临床相关霉菌的体外联合应用
Antimicrob Agents Chemother. 2014 Nov;58(11):6996-8. doi: 10.1128/AAC.03212-14. Epub 2014 Sep 8.
2
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.伏立康唑联合米卡芬净对念珠菌、曲霉菌、赛多孢属菌及茄病镰刀菌的作用。
Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.
3
In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.
J Med Microbiol. 2015 Mar;64(Pt 3):309-311. doi: 10.1099/jmm.0.000019. Epub 2015 Jan 16.
4
Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine.筛选化学文库以寻找针对烟曲霉的新型抗真菌药物，揭示了神经鞘脂类参与米替福新的作用机制。
mBio. 2021 Aug 31;12(4):e0145821. doi: 10.1128/mBio.01458-21. Epub 2021 Aug 10.
5
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.米替福新作为单一药物以及与伏立康唑或泊沙康唑联合使用对罕见丝状真菌病原体的体外活性。
J Antimicrob Chemother. 2013 Dec;68(12):2842-6. doi: 10.1093/jac/dkt282. Epub 2013 Jul 16.
6
Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method.真菌性角膜炎病原菌及致病真菌对治疗药物的纸片扩散法药敏研究
Curr Eye Res. 2015;40(11):1095-101. doi: 10.3109/02713683.2015.1056802. Epub 2015 Aug 13.
7
Natamycin and Azithromycin Are Synergistic against Ocular Pathogenic Aspergillus flavus Species Complex and Fusarium solani Species Complex Isolates.纳他霉素与阿奇霉素对眼部致病曲霉属黄曲霉种复合体和茄病镰刀菌种复合体分离株具有协同作用。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00077-18. Print 2018 Jul.
8
Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.使用Sensititre法对常见和罕见曲霉菌种进行泊沙康唑及其他抗霉菌活性唑类药物的药敏试验。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00168-17. Print 2017 Jun.
9
Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.APX001A（曼戈匹克斯）和对照剂对 2017 年国际监测项目中收集的 1706 株真菌分离株的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00840-19. Print 2019 Aug.
10
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.2017-2018 年 SENTRY 抗真菌监测计划中，伊曲康唑与机会性丝状真菌病原体的体外活性。
Diagn Microbiol Infect Dis. 2020 May;97(1):115007. doi: 10.1016/j.diagmicrobio.2020.115007. Epub 2020 Jan 29.
引用本文的文献
1
Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.以真菌脂质合成作为抗真菌药物研发及增强现有抗真菌药物效果的靶点。
NPJ Antimicrob Resist. 2025 Apr 12;3(1):27. doi: 10.1038/s44259-025-00093-4.
2
Miltefosine: A Repurposing Drug against Mucorales Pathogens.米替福新：一种用于治疗毛霉目病原体的重新利用药物。
J Fungi (Basel). 2023 Dec 4;9(12):1166. doi: 10.3390/jof9121166.
3
Potential Inhibitory Effect of Miltefosine against Terbinafine-Resistant .米替福新对特比萘芬耐药的潜在抑制作用
Pathogens. 2023 Apr 17;12(4):606. doi: 10.3390/pathogens12040606.
4
Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.口服载米替福新的海藻酸钠纳米粒，用聚山梨酯 80 修饰，用于治疗隐球菌性脑膜炎。
J Antimicrob Chemother. 2023 Apr 3;78(4):1092-1101. doi: 10.1093/jac/dkad053.
5
In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Strains.米替福新对一组唑类和棘白菌素耐药菌株的体外抗真菌药敏谱
J Fungi (Basel). 2022 Jul 4;8(7):709. doi: 10.3390/jof8070709.
6
Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine.筛选化学文库以寻找针对烟曲霉的新型抗真菌药物，揭示了神经鞘脂类参与米替福新的作用机制。
mBio. 2021 Aug 31;12(4):e0145821. doi: 10.1128/mBio.01458-21. Epub 2021 Aug 10.
7
Miltefosine Against and Species: Antifungal Activity and Its Effects on Fungal Cells.米替福新抗 和 种属：抗真菌活性及其对真菌细胞的影响。
Front Cell Infect Microbiol. 2021 Jul 23;11:698662. doi: 10.3389/fcimb.2021.698662. eCollection 2021.
8
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.体外和体内抗真菌联合用药评估技术
J Fungi (Basel). 2021 Feb 4;7(2):113. doi: 10.3390/jof7020113.
9
Carrier-Mediated Drug Uptake in Fungal Pathogens.真菌病原体中的载体介导药物摄取。
Genes (Basel). 2020 Nov 9;11(11):1324. doi: 10.3390/genes11111324.
10
Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.临床多育卷枝毛霉分离株的抗真菌药敏谱及耐药机制
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00318-20.
本文引用的文献
1
Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole.烟曲霉仅携带 Y121F 突变时对伏立康唑的敏感性降低，但对伊曲康唑和泊沙康唑的敏感性保持不变。
J Antimicrob Chemother. 2014 Dec;69(12):3244-7. doi: 10.1093/jac/dku316. Epub 2014 Aug 13.
2
Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.血液系统疾病患者确诊或疑似侵袭性真菌病抗真菌联合治疗的可行性、安全性和有效性多中心监测研究：SEIFEM真实世界联合研究
Mycoses. 2014 Jun;57(6):342-50. doi: 10.1111/myc.12161. Epub 2013 Dec 23.
3
Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health.由于农业领域使用唑类药物，导致对唑类耐药的烟曲霉菌株出现，这对人类健康构成了日益严重的威胁。
PLoS Pathog. 2013 Oct;9(10):e1003633. doi: 10.1371/journal.ppat.1003633. Epub 2013 Oct 24.
4
Azole resistance in Aspergillus fumigatus: a growing public health concern.烟曲霉唑类耐药性：日益严重的公共卫生问题。
Curr Opin Infect Dis. 2013 Dec;26(6):493-500. doi: 10.1097/QCO.0000000000000005.
5
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.体内三唑类药物和棘白菌素联合治疗侵袭性肺曲霉病：增强对 Cyp51 突变株的疗效。
Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.
6
Synthesis and antifungal activities of miltefosine analogs.米替福新类似物的合成与抗真菌活性。
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4828-31. doi: 10.1016/j.bmcl.2013.06.096. Epub 2013 Jul 6.
7
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.米替福新作为单一药物以及与伏立康唑或泊沙康唑联合使用对罕见丝状真菌病原体的体外活性。
J Antimicrob Chemother. 2013 Dec;68(12):2842-6. doi: 10.1093/jac/dkt282. Epub 2013 Jul 16.
8
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor Response to the Azole.两性霉素B次优剂量联合伏立康唑在对唑类药物反应不佳的烟曲霉感染小鼠模型中的疗效
Antimicrob Agents Chemother. 2013 Sep;57(9):4540-4542. doi: 10.1128/AAC.00563-13. Epub 2013 Jun 24.
9
Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: successful treatment with argatroban.真菌性败血症连续性肾脏替代治疗中反复出现体外循环凝血：阿加曲班治疗成功。
Am J Med Sci. 2013 Mar;345(3):256-8. doi: 10.1097/MAJ.0b013e3182711e59.
10
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.米替福新在隐球菌性脑膜脑炎和播散性隐球菌病的鼠模型中活性有限。
Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.
Zotero 插件